Aethlon Medical (AEMD) Reports Q1 Loss of $0.28

Go back to Aethlon Medical (AEMD) Reports Q1 Loss of $0.28

Aethlon Medical Announces Fiscal 2017 First Quarter Results

August 11, 2016 4:15 PM EDT

SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal first quarter year ended June 30, 2016.

Aethlon's lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that provides broad-spectrum elimination of infectious viruses and cancer-promoting exosomes from the circulatory system. In collaboration with its majority-owned Exosome Sciences, Inc. (ESI) subsidiary, the company is focused on the discovery of exosome-based biomarkers to diagnose and monitor a wide range of disease conditions. 

Corporate... More